CA-4948

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

CA-4948 (AU-4948) 是一种新型有效、选择性、口服生物可利用的 IRAK4 抑制剂。

CA-4948 (AU-4948) is a novel potent, selective, orally bioavailable IRAK4 inhibitor; shows in vivo activity in TLR4-induced cytokine release model, exhibits dose-dependent efficacy in ABC-DLBCL MYD88-L265P xenograft tumor models; a therapeutic agent for hematological cancers with dysregulated TLR/MYD88/IRAK4 signaling,?induces tumor regression in an ABC-DLBCL xenograft model combined with Venetoclax.Blood Cancer Phase 1 Clinical(In Vitro):IRAK4-IN-7 has anti-cancer and anti-inflammatory activities, it can be used for cancer and inflammatory diseases treatment.

——

IRAK4-IN-7 has anti-cancer and anti-inflammatory activities, it can be used for cancer and inflammatory diseases treatment.

CA 4948 | CA4948 | AU-4948 | AU 4948 | AU4948

Immunology/Inflammation

IRAK

IRAK

Cancer

Blood cancer

1801343-74-7

417.429

C21H19N7O3

>98% (HPLC)

DMSO : 13.89 mg/mL 33.28 mM;H2O : < 0.1 mg/mL

O=C(C1=CC=CC(C2=CC=C(N)N=C2)=N1)NC3=CN=C4C(OC(N5CCOCC5)=N4)=C3

6'-amino-N-(2-morpholinooxazolo[4,5-b]pyridin-6-yl)-[2,3'-bipyridine]-6-carboxamide

(-20℃)

With Ice Pack

≥ 2 years